Department of Avian and Rabbit Medicine, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.
Veterinary Medicine Directorate, Mansoura, Egypt.
Open Vet J. 2024 Jan;14(1):90-107. doi: 10.5455/OVJ.2024.v14.i1.9. Epub 2024 Jan 31.
Being a ubiquitous, highly contagious virus with a continuous mutation and a large number of evolutions worldwide, the infectious bronchitis virus (IBV) continues to wreak problems among Egyptian chickens and generate economic losses. The commonly applied IBV vaccination protocols in broilers include alternatives to classic and/or variant attenuated live virus vaccines.
The current study targeted to assess the protective efficacy of concurrent and successive Ma5 and 4/91 vaccine strain regimens against the field variant II IBV strain (IBV-EGY-ZU/Ck-127/2021) in chickens.
Commercial broiler chickens were vaccinated with Ma5 and 4/91 strains simultaneously at 1 and 14 days of age. The evaluation parameters included clinical protection and humoral and early innate immunity aspects in the renal tissues of vaccinated and infected birds.
The vaccine regimen ameliorated the clinical and histopathological lesions against variant II IBV and enhanced body gain as well as succeeded in preventing tracheal shedding and minimizing cloacal shedding of the field virus. The IL-1β mRNA gene expression was evident as early as 24 hours, with highly significant upregulation at 48 hours post vaccination and 24 hours post challenge (PC) in vaccinated birds. Remarkable upregulation was observed in oligoadenylate synthetases (OAS) expression 48 hours PC in vaccinated and unvaccinated infected birds. The vaccinated birds developed a significant antibody titer of 704.0 ± 111.98 at 28 days of age, with a consistent antibody titer increase after the challenge.
Overall, a combination of heterologous protectotype commercial vaccines achieved good protection against the Egyptian variant II IBV strain. This vaccine program could be an effective protocol against the threat posed by IBV viruses circulating in the Egyptian field.
传染性支气管炎病毒(IBV)是一种具有广泛传播性、高度传染性且不断变异和进化的病毒,在埃及的鸡群中持续引发问题并造成经济损失。目前在肉鸡中应用的 IBV 疫苗接种方案包括经典和/或变异减毒活病毒疫苗的替代方案。
本研究旨在评估 Ma5 和 4/91 疫苗株同时和连续接种方案对鸡群中野毒株 II 型 IBV(IBV-EGY-ZU/Ck-127/2021)的保护效果。
商业肉鸡在 1 日龄和 14 日龄时同时接种 Ma5 和 4/91 株。评估参数包括接种和感染鸡的临床保护、体液和早期固有免疫方面,以及肾脏组织中的变化。
该疫苗方案改善了对野毒株 II 型 IBV 的临床和组织病理学病变,提高了体重增长,并成功阻止了气管脱落和减少了野病毒的泄殖腔脱落。IL-1βmRNA 基因表达在接种后 24 小时即可检测到,接种后 48 小时和 24 小时攻毒时显著上调。在接种和未接种感染鸡的攻毒后 48 小时,寡聚腺苷酸合成酶(OAS)表达显著上调。接种鸡在 28 日龄时产生了 704.0±111.98 的显著抗体滴度,并在攻毒后持续增加。
总之,异源保护型商业疫苗的联合应用对埃及野毒株 II 型 IBV 实现了良好的保护效果。该疫苗方案可能是针对埃及田间流行的 IBV 病毒威胁的有效方案。